CASE REPORT article
Front. Immunol.
Sec. Inflammation
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1720992
This article is part of the Research TopicEvolving paradigms: IL-5's role in eosinophilic pathologies and targeted treatmentsView all articles
A Potential Novel Treatment for Drug-Induced Acute Interstitial Nephritis: Benralizumab A case presentation
Provisionally accepted
Alexander Saadia1
Aviv Talmon2*
Ron Wald3
Assaf Potruch2Michal Elhalel Dranitzki2Galina Pizov2Karen Meir2Kobi Gorin2Inon Sarig2Eyal Ben Dori2
Limor Rubin2Yaarit Ribak2
Yuval Tal2- 1Hadassah Medical Center, Jerusalem, Israel
- 2Hadassah University Medical Center, Jerusalem, Israel
- 3St Michael's Hospital, Toronto, Canada
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
A 55-year-old man presented to the emergency department (ED) with diffuse abdominal pain, vomiting, and anuria following a night of heavy alcohol intake. The patient's medical history included hypertension. Two weeks prior to presentation, he was prescribed etoricoxib for back pain. On presentation, he was found to have severe acute kidney injury, and dialysis was initiated. Renal biopsy showed acute interstitial nephritis with numerous eosinophilic infiltrates. Despite stopping etoricoxib and initiating high-dose steroids, kidney function did not improve. The administration of benralizumab—an anti-CD125 antibody—resulted in rapid and complete recovery of kidney function. This case report highlights the potential role of benralizumab in the treatment of drug-induced interstitial nephritis with eosinophiluria.
Keywords: Acute interstitial nephritis (AIN), IL-5 antibody, benralizumab, Dialysis, Acute kindey injury
Received: 08 Oct 2025; Accepted: 21 Oct 2025.
Copyright: © 2025 Saadia, Talmon, Wald, Potruch, Elhalel Dranitzki, Pizov, Meir, Gorin, Sarig, Ben Dori, Rubin, Ribak and Tal. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Aviv Talmon, talmon.aviv@gmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.